The Fly | OCUL

Over a week ago

Blair adds American Express, Oracle to Conviction List in monthly update

+39

Jul 1, 6:56 AM

Ocular Therapeutix price target raised by $4 at H.C. Wainwright, here's why

OCUL

Jun 18, 11:15 AM

Ocular Therapeutix price target raised by $6 at Baird, here's why

OCUL

Jun 18, 6:26 AM

Ocular Therapeutix trading resumes

OCUL

Jun 17, 9:15 AM

Ocular Therapeutix to resume trading at 9:15 am ET

OCUL

Jun 17, 8:53 AM

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

OCUL

Jun 17, 8:51 AM

Ocular Therapeutix trading halted, news pending

OCUL

Jun 17, 8:40 AM

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

OCUL

May 5, 7:49 AM

Ocular Therapeutix enrolls first patient in Axpali trial

OCUL

Apr 29, 7:25 AM

Ocular Therapeutix reports additional Axpaxli trial data

OCUL

Apr 13, 7:15 AM

Ocular Therapeutix price target raised by $3 at BofA, here's why

OCUL

Mar 3, 6:45 AM

Ocular Therapeutix price target raised by $7 at Clear Street, here's why

OCUL

Mar 2, 4:03 PM

What You Missed On Wall Street On Tuesday

+26

Feb 17, 4:31 PM

Ocular Therapeutix selloff brings attractive entry point, says Citizens

OCUL

Feb 17, 2:12 PM

Midday Fly By: Warner Bros. reopens Paramount talks

+26

Feb 17, 11:56 AM

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

OCUL

Feb 17, 10:50 AM

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

OCUL

Feb 17, 7:11 AM

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

OCUL

Feb 5, 7:04 AM

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

Jan 21, 7:03 AM

Unusually active option classes on open January 16th

Jan 16, 9:40 AM

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

Jan 15, 11:02 AM

Ocular Therapeutix rises 11.7%

OCUL

Jan 15, 10:01 AM

Ocular Therapeutix price target raised by $3 at BofA, here's why

OCUL

Dec 12, 8:31 AM

Mizuho remains bullish on EyePoint as competitor makes move for 'Pole Position'

Dec 9, 11:10 AM

Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans

OCUL

Dec 8, 7:38 AM

Proprietary Sustained-Release Technology: Their bioresorbable hydrogel platform enables sustained drug delivery over weeks to months, a significant advancement over traditional eye drops.

Broad Pipeline and Platform Versatility: The hydrogel technology is adaptable across multiple therapeutic areas, supporting a diverse pipeline including glaucoma, wet AMD, dry eye, and surgical pain.

Validated FDA-Approved Product: DEXTENZA, their first FDA-approved product, demonstrates the commercial viability and regulatory acceptance of their sustained-release approach.

Unfavorable Clinical Trial Results: The success of pipeline candidates, such as OTX-TKI for glaucoma and OTX-TIC for wet AMD, depends entirely on positive outcomes from ongoing and future clinical trials, and any setbacks could significantly impact the company's value:

Regulatory Approval Challenges: Despite DEXTENZA's approval, future product candidates face rigorous regulatory hurdles, and failure to obtain or maintain necessary approvals from the FDA and other global authorities would prevent commercialization:

Limited Commercial Success and Market Adoption: The successful commercialization of DEXTENZA and future products hinges on market acceptance, physician adoption, and adequate reimbursement, which may not materialize as anticipated due to competition or other factors:

Proprietary Sustained-Release Technology: Their bioresorbable hydrogel platform enables sustained drug delivery over weeks to months, a significant advancement over traditional eye drops.

Broad Pipeline and Platform Versatility: The hydrogel technology is adaptable across multiple therapeutic areas, supporting a diverse pipeline including glaucoma, wet AMD, dry eye, and surgical pain.

Validated FDA-Approved Product: DEXTENZA, their first FDA-approved product, demonstrates the commercial viability and regulatory acceptance of their sustained-release approach.